Vanda Pharmaceuticals Files 8-K: Material Agreement Details
Ticker: VNDA · Form: 8-K · Filed: Apr 17, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.001, $25.00, $1 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action, filing
Related Tickers: VNDA
TL;DR
Vanda Pharma filed an 8-K on 4/17, looks like a big deal with their securities.
AI Summary
On April 17, 2024, Vanda Pharmaceuticals Inc. announced a material definitive agreement related to its securities. The company also reported on other events and filed financial statements and exhibits. Specific details regarding the agreement, modifications to security holder rights, and amendments to its articles of incorporation or bylaws were not fully disclosed in this initial filing.
Why It Matters
This filing indicates a significant corporate event for Vanda Pharmaceuticals, potentially impacting its structure, operations, or shareholder rights.
Risk Assessment
Risk Level: medium — The filing mentions material definitive agreements and modifications to security holder rights, which can introduce significant changes and potential risks.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- April 17, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement Vanda Pharmaceuticals entered into?
The filing indicates the entry into a material definitive agreement but does not provide specific details about its nature in the provided text.
What modifications were made to the rights of Vanda Pharmaceuticals' security holders?
The filing states there were material modifications to the rights of security holders, but the specifics are not detailed in the provided text.
Were there any amendments to Vanda Pharmaceuticals' articles of incorporation or bylaws?
The filing lists 'Amendments to Articles of Incorporation or Bylaws' as an item information, suggesting potential changes, but the details are not provided.
What is the significance of the 'Other Events' listed in the filing?
The filing notes 'Other Events' as an item information, implying additional corporate activities occurred, but the specific events are not described in the provided text.
When was this 8-K filing submitted and what period does it cover?
The filing was submitted on April 17, 2024, and the date of the earliest event reported is also April 17, 2024.
Filing Stats: 2,514 words · 10 min read · ~8 pages · Grade level 12.2 · Accepted 2024-04-17 17:19:33
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma
- $25.00 — of the Company at an exercise price of $25.00 (the "Exercise Price"), subject to adju
- $1 — ders upon liquidation either to receive $1 per one one-thousandth of a share of Pr
Filing Documents
- d795618d8k.htm (8-K) — 49KB
- d795618dex31.htm (EX-3.1) — 28KB
- d795618dex41.htm (EX-4.1) — 355KB
- d795618dex991.htm (EX-99.1) — 9KB
- d795618dex992.htm (EX-99.2) — 6KB
- 0001193125-24-099251.txt ( ) — 676KB
- vnda-20240417.xsd (EX-101.SCH) — 3KB
- vnda-20240417_lab.xml (EX-101.LAB) — 18KB
- vnda-20240417_pre.xml (EX-101.PRE) — 11KB
- d795618d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amended and Restated Certificate of Designation of Rights, Preferences and Privileges of Series A Junior Participating Preferred Stock of Vanda Pharmaceuticals Inc. 4.1 Rights Agreement, dated as of April 17, 2024, by and between Vanda Pharmaceuticals Inc. and Equiniti Trust Company, LLC as rights agent. 99.1 Press Release of Vanda Pharmaceuticals Inc. dated April 17, 2024 Announcing the Adoption of a Limited Duration Stockholder Rights Plan. 99.2 Press Release of Vanda Pharmaceuticals Inc. dated April 17, 2024, Confirming Rejection of Unsolicited Takeover Proposals from Future Pak. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 17, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary